Morgan Lewis Advises Biopharmaceutical Formulation Technology Company Elektrofi in Halozyme Therapeutics Acquisition Agreement
October 01, 2025NEW YORK and BOSTON, October 1, 2025: Morgan Lewis is representing Elektrofi, Inc. in the company’s definitive agreement to be acquired by Halozyme Therapeutics, Inc. The transaction is comprised of an upfront payment of $750 million and up to three $50 million milestone payments contingent on three separate product approvals.
Elektrofi is a biopharmaceutical formulation technology company that is focused on improving the delivery of biologic therapies by giving patients the ability to control how they want to receive and benefit from life-changing medicines. Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies.
Partners Russell Franklin, Mike Conza, and Andrew Haupt and associates Lindsay Mozdziock and Anna Ellement are advising Elektrofi.